Evidence map›Paper›PMID 27101408›Full record

ArticlePloS one2016

Placental Kisspeptins Differentially Modulate Vital Parameters of Estrogen Receptor-Positive and -Negative Breast Cancer Cells.

Zahra Rasoulzadeh, Roya Ghods, Tohid Kazemi, Ebrahim Mirzadegan, Nassim Ghaffari-Tabrizi-Wizsy, Simin Rezania, Somaieh Kazemnejad, Soheila Arefi, Jamileh Ghasemi, Sedigheh Vafaei and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Zahra RasoulzadehDepartment of Immunology, Tabriz University of Medical Sciences, Tabriz, 5165683146, Iran.
Roya GhodsDepartment of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, IUMS, Tehran, 1449614535, Iran.
Tohid KazemiImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, 5165683146, Iran.
Ebrahim MirzadeganImmunobiology Research Center, Avicenna Research Institute, ACECR, Tehran, 1177-19615, Iran.
Nassim Ghaffari-Tabrizi-WizsySFL Chicken CAM Lab, Institute of Pathophysiology and Immunology, Medical University of Graz, Graz, 8010, Austria.
Simin RezaniaInstitute of Biophysics, Medical University of Graz, Graz, 8010, Austria.
Somaieh KazemnejadReproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, 1177-19615, Iran.
Soheila ArefiReproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, 1177-19615, Iran.
Jamileh GhasemiNanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, 1177-19615, Iran.
Sedigheh VafaeiNanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, 1177-19615, Iran.
Ahmad-Reza MahmoudiMonoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, 1177-19615, Iran.
Amir-Hassan ZarnaniNanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, 1177-19615, Iran.
Academic Center for Education, Culture and Research · IRMedical University of Graz · ATTabriz University of Medical Sciences · IRIran University of Medical Sciences · IRRoyan Institute · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kisspeptins (KPs) are major regulators of trophoblast and cancer invasion. Thus far, limited and conflicting data are available on KP-mediated modulation of breast cancer (BC) metastasis; mostly based on synthetic KP-10, the most active fragment of KP. Here, we report for the first time comprehensive functional effects of term placental KPs on proliferation, adhesion, Matrigel invasion, motility, MMP activity and pro-inflammatory cytokine production in MDA-MB-231 (estrogen receptor-negative) and MCF-7 (estrogen receptor-positive). KPs were expressed at high level by term placental syncytiotrophoblasts and released in soluble form. Placental explant conditioned medium containing KPs (CM) significantly reduced proliferation of both cell types compared to CM without (w/o) KP (CM-w/o KP) in a dose- and time-dependent manner. In MDA-MB-231 cells, placental KPs significantly reduced adhesive properties, while increased MMP9 and MMP2 activity and stimulated invasion. Increased invasiveness of MDA-MB-231 cells after CM treatment was inhibited by KP receptor antagonist, P-234. CM significantly reduced motility of MCF-7 cells at all time points (2-30 hr), while it stimulated motility of MDA-MB-231 cells. These effects were reversed by P-234. Co-treatment with selective ER modulators, Tamoxifen and Raloxifene, inhibited the effect of CM on motility of MCF-7 cells. The level of IL-6 in supernatant of MCF-7 cells treated with CM was higher compared to those treated with CM-w/o KP. Both cell types produced more IL-8 after treatment with CM compared to those treated with CM-w/o KP. Taken together, our observations suggest that placental KPs differentially modulate vital parameters of estrogen receptor-positive and -negative BC cells possibly through modulation of pro-inflammatory cytokine production.

Indexed as

ApoptosisCell MovementAdultBlotting, WesternBreast NeoplasmsCell ProliferationFemaleHumansImmunoenzyme TechniquesImmunoprecipitationKisspeptinsPlacentaPregnancyReal-Time Polymerase Chain ReactionReceptors, EstrogenReverse Transcriptase Polymerase Chain ReactionKISS1 protein, humanKisspeptinsReceptors, EstrogenRNA, Messenger

Identifiers

PMID27101408
PMCPMC4839747
OpenAlexW2339081016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.